Skip to main content
Open
Question
Forecasts
Track record
Unknowns
How it works
Sources
FAQ
Menu
← Evidence map
Review
Herz
2022
[Cost-benefit analysis of new lipid-lowering agents].
Christopher Blaum et al.
PubMed ↗
Publisher ↗
No numbers read from the abstract.
Not cited yet
[Cost-benefit analysis of new lipid-lowering agents]. | OpenQuestion